Aspira Pathlab & Diagnostics Limited is an India-based company, which is engaged in the business of running, owning, managing, and administering Diagnostics Centers. The principal activities of the Company consist of pathology investigation services, radiology investigation services and other related healthcare services at diagnostic centers in Mumbai. The Company carries out pathological investigations in various branches, including biochemistry, hematology, histopathology, microbiology, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The Company's tests include pathology test, sonography, x-ray, and radiology. Its pathology tests include Influenza (Flu) Panel with H3N2, Blood chromosome analysis, Filmarray multiplex PCR(BIOFIRE) Pneumonia Panel Plus, Polycystic Ovarian Syndrome (PCOS) 2, Typhoid PCR, Dengue-Chikungunya-Malaria multiplex PCR, Vitamin And TSH, Fever screening profile-2, and others.
Aspira Pathlab & Diagnostics L Financial Highlights
- Revenue: Aspira Pathlab & Diagnostics L reported revenue of ₹22.39 crore in FY25 vs ₹13.62 crore in FY24. It showed an increase of 64.39% on a yearly basis.
- Operating Profit: Aspira Pathlab & Diagnostics L reported an operating profit of ₹2.02 crore in FY25 vs ₹2.67 crore in FY24. It showed an increase of 175.66% on a year-on-year basis.
- Net Profit: Aspira Pathlab & Diagnostics L reported a net profit of ₹2.02 crore in FY25 vs ₹2.67 crore in FY24. It showed an increase of 175.66% on a yearly basis.
Aspira Pathlab & Diagnostics L Quarterly Result Highlights
- Aspira Pathlab & Diagnostics L reported revenue of ₹5.36 crore in Jun 2025, compared with ₹5.91 crore in Mar 2025, representing a decrease of 9.31% on a quarter-on-quarter (QoQ) basis.
- Aspira Pathlab & Diagnostics L reported an operating profit of ₹0.42 crore in Jun 2025, compared with ₹0.68 crore in Mar 2025, representing a decrease of 38.24% on a quarter-on-quarter (QoQ) basis.
- Aspira Pathlab & Diagnostics L reported a profit of ₹0.42 crore in Jun 2025, compared with ₹0.68 crore in Mar 2025, reflecting a decrease of 38.24% on a QoQ basis.
- The earnings per share (EPS) of Aspira Pathlab & Diagnostics L stood at ₹1.97 during Jun 2025.
